Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

View 0 Studies Requested

Effect of Aspirin on Biomarkers of Barrett’s Esophagus After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation

Trial Summary

This randomized placebo-controlled phase II trial studies the safety of and how well aspirin works in preventing Barrett’s esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett’s esophagus for the levels of a specific protein that is linked to developing Barrett’s esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.

Patients are randomized to 1 of 2 treatment arms.


  • ARM I: Patients receive aspirin orally (PO) once daily (QD) for 12 months.
  • ARM II: Patients receive placebo PO QD for 12 months.